Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2017

16.01.2017 | Original Article – Clinical Oncology

Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting

verfasst von: Thomas M. Atkinson, Lauren J. Rogak, Narre Heon, Sean J. Ryan, Mary Shaw, Liora P. Stark, Antonia V. Bennett, Ethan Basch, Yuelin Li

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concordance metrics (e.g., intraclass correlation) may not capture nuanced aspects of the association between clinician and patient-graded AEs, we aimed to characterize differences in AE grading thresholds between doctors (MDs), registered nurses (RNs), and patients using the Bayesian Graded Item Response Model (GRM).

Methods

From the medical charts of 393 patients aged 26–91 (M = 62.39; 43% male) receiving chemotherapy, we retrospectively extracted MD, RN and patient AE ratings. Patients reported using previously developed Common Terminology Criteria for Adverse Events (CTCAE) patient-language adaptations called STAR (Symptom Tracking and Reporting). A GRM was fitted to calculate the latent grading thresholds between MDs, RNs and patients.

Results

Clinicians have overall higher average grading thresholds than patients when assessing diarrhea, dyspnea, nausea and vomiting. However, RNs have lower grading thresholds than patients and MDs when assessing constipation. The GRM shows higher variability in patients’ AE grading thresholds than those obtained from clinicians.

Conclusions

The present study provides evidence to support the notion that patients report some AEs that clinicians might not consider noteworthy until they are more severe. The availability of GRM methodology could serve to enhance clinical understanding of the patient symptomatic experience and facilitate discussion where AE grading discrepancies exist. Future work should focus on capturing explicit AE grading decision criteria from MDs, RNs, and patients.
Literatur
Zurück zum Zitat Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Supp Care Cancer 24:3669–3676. doi:10.1007/s00520-016-3297-9 CrossRef Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Supp Care Cancer 24:3669–3676. doi:10.​1007/​s00520-016-3297-9 CrossRef
Zurück zum Zitat Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K et al (2007a) Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 14(3):264–268. doi:10.1197/jamia.M2177 Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K et al (2007a) Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 14(3):264–268. doi:10.​1197/​jamia.​M2177
Zurück zum Zitat Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, ... Schrag, D (2007b) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374–5380. doi:10.1200/JCO.2007.11.2243 Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, ... Schrag, D (2007b) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374–5380. doi:10.​1200/​JCO.​2007.​11.​2243
Zurück zum Zitat Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst, 106(9). doi:10.1093/jnci/dju244 Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst, 106(9). doi:10.​1093/​jnci/​dju244
Zurück zum Zitat Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ et al (2015) Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials. doi:10.1177/1740774515615540 PubMed Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ et al (2015) Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials. doi:10.​1177/​1740774515615540​ PubMed
Zurück zum Zitat Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. doi:10.1200/JCO.2015.63.0830 CrossRefPubMed Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. doi:10.​1200/​JCO.​2015.​63.​0830 CrossRefPubMed
Zurück zum Zitat Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20(12):1929–1935. doi:10.1093/annonc/mdp287 CrossRefPubMed Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20(12):1929–1935. doi:10.​1093/​annonc/​mdp287 CrossRefPubMed
Zurück zum Zitat Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ et al (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. doi:10.1001/jamaoncol.2015.2639 PubMedPubMedCentral Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ et al (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. doi:10.​1001/​jamaoncol.​2015.​2639 PubMedPubMedCentral
Zurück zum Zitat Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G et al (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257–269. doi:10.1007/s11136-013-0470-1 CrossRefPubMed Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G et al (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257–269. doi:10.​1007/​s11136-013-0470-1 CrossRefPubMed
Zurück zum Zitat Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 199–205 Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 199–205
Zurück zum Zitat R Development Core Team (2016) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. http://www.R-project.org. Accessed 9 Dec 2016 R Development Core Team (2016) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. http://​www.​R-project.​org. Accessed 9 Dec 2016
Zurück zum Zitat Rosner B (2005) Fundamentals of biostatistics. Duxbury, Belmont Rosner B (2005) Fundamentals of biostatistics. Duxbury, Belmont
Zurück zum Zitat Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127CrossRefPubMed Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127CrossRefPubMed
Zurück zum Zitat Samejima F (1997) Graded response model Handbook of modern item response theory. Springer, New York, pp 85–100 Samejima F (1997) Graded response model Handbook of modern item response theory. Springer, New York, pp 85–100
Metadaten
Titel
Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting
verfasst von
Thomas M. Atkinson
Lauren J. Rogak
Narre Heon
Sean J. Ryan
Mary Shaw
Liora P. Stark
Antonia V. Bennett
Ethan Basch
Yuelin Li
Publikationsdatum
16.01.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2335-9

Weitere Artikel der Ausgabe 4/2017

Journal of Cancer Research and Clinical Oncology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.